A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lungLo M. Sosinski, Robert A. Quinn, Marc McClelland et al.|Journal of Cystic Fibrosis|2021Cited by 71
Complex and unexpected outcomes of antibiotic therapy against a polymicrobial infectionLydia-Ann J. Ghuneim, Robert A. Quinn, Isaac Klapper et al.|The ISME Journal|2022Cited by 35
Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapyChristian Martin, Robert A. Quinn, Marc McClelland et al.|Respiratory Research|2023Cited by 27
Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapyChristian Martin, Robert A. Quinn, Marc McClelland et al.|Research Square|2023Cited by 4
525: Elexacaftor/tezacaftor/ivacaftor therapy alters the CF lung mucus metabolome, reshaping microbiome niche spaceRobert A. Quinn, Douglas Conrad, Rajesh Thomas et al.|Journal of Cystic Fibrosis|2021Cited by 1